Multi-endpoint analysis of human 3D airway epithelium following repeated exposure to whole electronic vapor product aerosol or cigarette smoke.

Autor:	Czekala L; Imperial Brands PLC, 121 Winterstoke Road, Bristol BS3 2LL, United Kingdom., Wieczorek R; Reemtsma Cigarettenfabriken GmbH, An Imperial Brands PLC Company, Albert-EinsteinRing-7, D-22761 Hamburg, Germany., Simms L; Imperial Brands PLC, 121 Winterstoke Road, Bristol BS3 2LL, United Kingdom., Yu F; Imperial Brands PLC, 121 Winterstoke Road, Bristol BS3 2LL, United Kingdom., Budde J; Reemtsma Cigarettenfabriken GmbH, An Imperial Brands PLC Company, Albert-EinsteinRing-7, D-22761 Hamburg, Germany., Trelles Sticken E; Reemtsma Cigarettenfabriken GmbH, An Imperial Brands PLC Company, Albert-EinsteinRing-7, D-22761 Hamburg, Germany., Rudd K; Imperial Brands PLC, 121 Winterstoke Road, Bristol BS3 2LL, United Kingdom., Verron T; Imperial Brands PLC, 121 Winterstoke Road, Bristol BS3 2LL, United Kingdom., Brinster O; Reemtsma Cigarettenfabriken GmbH, An Imperial Brands PLC Company, Albert-EinsteinRing-7, D-22761 Hamburg, Germany., Stevenson M; Imperial Brands PLC, 121 Winterstoke Road, Bristol BS3 2LL, United Kingdom., Walele T; Imperial Brands PLC, 121 Winterstoke Road, Bristol BS3 2LL, United Kingdom.
Jazyk:	angličtina
Zdroj:	Current research in toxicology [Curr Res Toxicol] 2021 Feb 20; Vol. 2, pp. 99-115. Date of Electronic Publication: 2021 Feb 20 (Print Publication: 2021).
DOI:	10.1016/j.crtox.2021.02.004
Abstrakt:	Smoking is a cause of serious diseases in smokers including chronic respiratory diseases. This study aimed to evaluate the tobacco harm reduction (THR) potential of an electronic vapor product (EVP, my blu™) compared to a Kentucky Reference Cigarette (3R4F), and assessed endpoints related to chronic respiratory diseases. Endpoints included: cytotoxicity, barrier integrity (TEER), cilia function, immunohistochemistry, and pro-inflammatory markers. In order to more closely represent the user exposure scenario, we have employed the in vitro 3D organotypic model of human airway epithelium (MucilAir™, Epithelix) for respiratory assessment. The model was repeatedly exposed to either whole aerosol of the EVP, or whole 3R4F smoke, at the air liquid interface (ALI), for 4 weeks to either 30, 60 or 90 puffs on 3-exposure-per-week basis. 3R4F smoke generation used the ISO 20778:2018 regime and EVP aerosol used the ISO 20768:2018 vaping regime. Exposure to undiluted whole EVP aerosol did not trigger any significant changes in the level of pro-inflammatory mediators, cilia beating function, barrier integrity and cytotoxicity when compared with air controls. In contrast, exposure to diluted (1:17) whole cigarette smoke caused significant changes to all the endpoints mentioned above. To our knowledge, this is the first study evaluating the effects of repeated whole cigarette smoke and whole EVP aerosol exposure to a 3D lung model at the ALI. Our results add to the growing body of scientific literature supporting the THR potential of EVPs relative to combustible cigarettes and the applicability of the 3D lung models in human-relevant product risk assessments. Competing Interests: The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: All authors were employees of Imperial Brands PLC or subsidiaries at the time of this study. Imperial Brands PLC is the sole source of funding and sponsor of this project. Fontem Ventures B.V., the manufacturer of the EVP used in this study, is a wholly owned subsidiary of Imperial Brands PLC. (© 2021 The Authors.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu